Your browser doesn't support javascript.
loading
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
Panovská, Anna; Nemcová, Lucie; Nekvindová, Lucie; Spacek, Martin; Simkovic, Martin; Papajík, Tomás; Brejcha, Martin; Lysák, Daniel; Zuchnická, Jana; Novák, Jan; Starostka, David; Poul, Hynek; Vrbacký, Filip; Vodárek, Pavel; Urbanová, Renata; Plevová, Karla; Pospísilová, Sárka; Maslejová, Stanislava; Brychtová, Yvona; Koritáková, Eva; Smolej, Lukás; Doubek, Michael.
Afiliação
  • Panovská A; Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • Nemcová L; Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • Nekvindová L; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
  • Spacek M; 1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Simkovic M; 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
  • Papajík T; Department of Hematooncology, University Hospital, Olomouc, Czech Republic.
  • Brejcha M; Oncology Center, Nový Jicín, Czech Republic.
  • Lysák D; Department of Hematology and Oncology, University Hospital, Plzen, Czech Republic.
  • Zuchnická J; Department of Hematology, University Hospital, Ostrava, Czech Republic.
  • Novák J; Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Starostka D; Department of Hematology, Havirov Hospital and Polyclinic, Havírov, Czech Republic.
  • Poul H; Department of Hematology, Hospital Pelhrimov, Pelhrimov, Czech Republic.
  • Vrbacký F; 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
  • Vodárek P; 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
  • Urbanová R; Department of Hematooncology, University Hospital, Olomouc, Czech Republic.
  • Plevová K; Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • Pospísilová S; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Maslejová S; Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • Brychtová Y; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
  • Koritáková E; Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • Smolej L; Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
  • Doubek M; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
Hematol Oncol ; 38(4): 509-516, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32400885
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: República Tcheca